Introduction
Twenty-six researchers and industry representatives from nine different countries (USA, Spain, Italy, France, Germany, Switzerland, Sweden, The Netherlands, United Kingdom), one patient and representatives of SMA Europe and from the SMA Foundation met in Naarden on the weekend of the 19-21 of February 2016 to update current knowledge on standards of care (SOC) for spinal muscular atrophy (SMA).
Background
Spinal muscular atrophy (SMA) is a monogenic disorder, due to the mutations in the survival of motor neuron (SMN1) gene (5q11.2-q13.3). SMA has an incidence of about 1 in 11,000 live births [1] . It includes a wide range of phenotypes: very weak infants unable to sit unsupported (type 1), nonambulant children able to sit independently (type 2), up to ambulant children (type 3) and adults (type 4) [2, 3] . These maximal motor milestones may be lost over time (Table 1) .
Following recommendations at an International Conference on the Standard of Care for SMA in September 2004 [5] , a SMA standard of care committee was established and worked from January 2005 to create a consensus statement on SMA until publication of the report in August 2007 [6] . The core committee consisted of 12 expert clinicians in SMA (11 neurologists, 1 pulmonologist) and three consultants (1 from NIH, 2 from patient advocacy groups). Four working groups were established, each with a European and US co-leader, and addressed diagnostics/new interventions, pulmonary care, gastrointestinal/nutritional care, and orthopedic care/ rehabilitation. Palliative care was added subsequently. Six to eleven experts in these topics were then invited to participate in each working group. The committee identified the following goals for all four working groups: (1) to identify current care issues in SMA clinical practice, (2) to search for existing practices in SMA clinical care and the rationale or data supporting such practices, (3) to achieve consensus of the most appropriate medical practice in caring for patients with SMA, (4) to use this standard of care consensus to establish clinical care guidelines for future SMA clinical trials, (5) to identify future research directions in the care of SMA patients, and (6) to publish the consensus as guidelines for clinical care of SMA patients. Each working group then performed a detailed literature search and conducted conference calls to discuss their topics [6] . The Delphi technique was used to explore consensus expert opinion [7] . The goal of the Delphi technique is designed to identify if, in aggregation, there is a rank-ordered cluster of answers to a particular question from respondents that reflects group consensus. It also serves to identify if no consensus is present and where topics need further study. At least two rounds of the Delphi were performed for each specific question that was addressed. In addition, two in-person conferences were conducted to discuss the topics in an open forum and settle upon an agreeable written summary. Following publication of the report in 2007, the SMA SOC guidelines were widely adopted by SMA clinical care centers and have been promoted by patient advocacy groups since. Additionally, they were often included by pharmaceutical companies in clinical trial protocols as a benchmark for care during participation in a clinical trial.
Over the last decade many aspects of care for infants and children with SMA have dramatically improved, resulting in longer survival and better quality of life. Several papers have reported a large amount of data reflecting improvements in care in orthopedic management of scoliosis, nutrition, respiratory support and other aspects [8] [9] [10] [11] [12] [13] [14] . In recognition of these changes in the care of patients with SMA, it was felt that an update of SOC was needed. We proposed a new workshop that would comprehensively review the recent literature and take into account experts' opinions on current standards of care.
The aims of this workshop were:
a. Two leaders were then invited to head each topic, in most cases one from Europe and one from the United States. The WG leaders in turn were tasked to invite approximately ten clinicians with expertise in SMA, balancing participation from Europe and other countries. Each WG, if appropriate to the topic, was encouraged to include at least one patient or parent/ caregiver of a child with SMA to participate in the discussion. Similarly, representatives of the six pharmaceutical companies with drugs in clinical development for SMA were invited to review the drafts of the WG's deliberations and provide comment. The WG leaders, WG participants, patient advocacy representatives, patients/parents and industry participants are listed in the Appendix S1.
This workshop was preceded by 2 conference calls, and at least 2 web-based Delphi rounds of inquiry by each working group (WG). The coordinators participated in all WG to ensure homogeneity. The first round of Delphi inquiry was designed to generate specific topics from open-ended questions. The second round focused on the topics having the most common interest to the WG and ranked the highest on the first round. Ying Qian (SMA Foundation) provided analytical support and Becca Leary from TREAT NMD provided organization support to several of the working groups.
The initial consensus from these working groups was then presented at the Workshop for further discussion by the entire group and finalized for the publication.
When needed, further Delphi rounds were performed following the Workshop.
Each topic was summarized as to where:
• Consensus is reached with uniform opinion • Consensus is reached with a majority opinion, and with minority opinions mentioned • No consensus is reached and more work needs to be performed
The American Academy of Pediatrics policy statement: classifying recommendations for clinical practice guidelines (2004) was used as the structure for each working group to derive a specific recommendation as to the quality of the evidence in the literature, the relative strength of the recommendation as to providing benefit or harm [15] . Per these guidelines, "a strong recommendation means that the committee believes that the benefits of the recommended approach clearly exceed the harms of that approach (or, in the case of a strong negative recommendation, that the harms clearly exceed the benefits) and that the quality of the evidence supporting this approach is either excellent or impossible to obtain. Clinicians should follow such guidelines unless a clear and compelling rationale for acting in a contrary manner is present. A recommendation means that the committee believes that the benefits exceed the harms (or, in the case of a negative recommendation, that the harms exceed the benefits), but the quality of the evidence on which this recommendation is based is not as strong. Clinicians also generally should follow such guidance but also should be alert to new information and sensitive to patient preferences." The natural history of type 1, 2 and 3 SMA was discussed, focusing on how this has evolved in parallel with evolving standards of care.
Richard Finkel presented a review of published data on survival for SMA types 1, 2 and 3 [16] . upon intensity of care provided and the importance of the number of copies of the SMN2 gene as a prognostic biomarker. Table 2C summarizes the risk of loss of ambulation in SMA type 3 patients. To summarize the survival data from the type 1 studies cited here, a few conclusions can be drawn:
1 Earlier age of onset of symptoms is generally associated with shorter survival [25, 26] . Infants with type 1B (symptom onset <3 months of age) as a group have shorter survival than those with type 1C (symptom onset 3-6 months of age) [27] , but survival is similar when ventilation and nutritional support are provided [28] . 2 The number of copies of the SMN2 gene is a strong predictive biomarker: survival curves for SMA patients with 2 copies have a more rapid and linear decline than do those with 3 copies [25, [28] [29] [30] [8] . ii. When "reactive" ventilation and nutrition support were variably provided, following the clinical indication for this support, the mean/median age to the combined endpoint was 7.3/6.1 months and for those with 2 copies of the SMN2 gene was mean/median of 7.8/6.5 months [25] . iii. A prospective study showed the combined endpoint for those with 2 copies of the SMN2 gene was a median of 10.5 months [28] .
Survival in type 2 patients is now commonly into the 3rd decade and with one study having median survival to beyond age 40 years [36] . Survival for type 3 patients is normal [37] .
Recent studies, using motor and developmental assessments, have also explored longitudinal changes in motor function, showing how this continues to decline after diagnosis. At symptom onset type 1 infants generally have reduced motor skills, the majority will have no head control, and new motor skills are never subsequently achieved [38] . Thus, prolonged survival, with nutritional and ventilation support, does not enhance motor development.
Eugenio Mercuri reported data on type 2 and 3 SMA. With improvements in standard of care the overall natural history has improved compared to what was reported until two decades ago [37]. While early studies report a rapidly progressive loss of motor and respiratory function in type 2 SMA, recent studies suggest that the progression is much slower [39] . If considering one year of follow up, the mean changes in motor or respiratory function are minimal [40] even though a longer follow up will reveal some decline [39] . An international effort has recently been made to define trajectories of progression by using a large dataset combining data from large networks in US, UK and Italy. This effort confirmed that, using the Hammersmith Functional Motor Scale Expanded (HFMSE), the changes over 1 year are minimal but that different trajectories of progression can be identified [38] . Non-ambulant patients tend to improve before reaching the age of 5 years while after this age they will tend to show some decline. In ambulant patients, the profile is slightly different as the decline is more obvious in the years preceding puberty. The patients who showed a more rapid decline were those who developed contractures or severe scoliosis or a sudden increase in weight confirming that some aspects of care are extremely relevant in the progression of the disease. Francesco Muntoni (UK) reported how in SMA type 2 different standards of care can affect the progression of the disease, reporting the experience of their group on the effect of early monitoring and intervention in different aspects including nutrition, gastrostomy, early scoliosis and management of respiratory infection, on the progression of the disease.
Jes Rahbek reported the experience in a large cohort of type 2 adult patients. Despite the improvement in survival that makes the transition to adulthood and old age not just possible but very likely, the literature on adult type 2 SMA is still limited [41, 42] . A recent survey conducted in Denmark suggested that although adult patients are considered to be more stable compared to young prepubertal patients, deterioration in physical function and muscle strength can still occur [43] . The deterioration may affect different aspects. Contractures in shoulders, elbows and wrist extension can increase and tend to be increasingly asymmetrical over time. One major concern is a progressive limitation of mouth opening and more generally, orofacial problems affecting speech and eating that can be found in all age groups but tend to increase over time and can also affect ventilator use. These aspects are often underestimated and not discussed adequately with adult patients and, as suggested by the recent survey, standards of care should be implemented to include recommendations also for them.
Setting the frame: 2. Standards of care and clinical trials
In this session the discussion focused on how SOC has been addressed in SMA clinical trials. Richard Finkel and Enrico Bertini (Italy) reported a review of the existing trials in type 1 and 2 SMA in order to assess if different standards of care had been used to establish inclusion/exclusion criteria or stratification of the existing clinical trials.
In clinical trial for type 1 patients there were often requirements for infants being stable in the weeks before enrollment, and for concordance with the published 2007 standard of care guidelines. Trial criteria have, however, generally lacked specific suggestions on palliative versus proactive care. This is an important point as multicenter studies can be challenged by variability in SOC among the sites and even within the same site some variability is due to the fact that parental autonomy must be maintained. This has been the object of several discussions with ethicists, regulators and advocacy groups trying on one side to allow parental decisions about palliative care, while supporting the participant for sufficient time to respond to drug [44] .
In type 2, severe scoliosis or scoliosis surgery, severe contractures, and need for ventilation above 13 hours have been used as exclusion criteria in recent and current studies. No additional specific gastrointestinal/nutrition issues have been considered, apart from generally requiring the patient to be healthy and meet the inclusion criteria of the study. Some studies also suggested that participants should follow the published guidelines on care standard for SMA without going into more details. One study using an AAV9 gene transfer therapy in type 1 SMA did require swallow studies to be performed at the screening visit and if aspiration was identified then supplemental feeding was required for entry into the study. The possibility that new therapies for SMA may improve aspects of care and overall well-being, such as reducing the number of respiratory infections and hospital admissions, was also discussed. Patients with SMA have many co-morbidities which have been identified as adverse events in recent studies. These are potentially amenable to improvement and need to be considered as part of the standard of care of the patient with SMA.
Agata Robertson (UK) reported the results of a recent survey in UK and provided an overview of how TREAT-NMD developed global registries, including data from 24 national registries around the world. This allowed mapping some differences in care standards and to highlight areas of controversies that require further discussion.
Patient perspective
Anna Wittchen contributed that physician access is difficult for adults with type 2, especially emergent care for adults who may not be able to speak effectively for themselves. Women's issues and pregnancy also need further attention -how to maintain motor and respiratory function during a pregnancy and the need to educate obstetricians on treatment of the pregnant woman with a neuromuscular disorder. Transition from a pediatric to an adult clinic and hospital remains a challenge for many patients and warrants further attention. Mencia de Lemus highlighted the importance of having guidelines on how to handle emergencies (anesthetics, intubation, oxygen, antibiotics) as this is where patients can be in a more vulnerable situation, and having a consensus about these issues could be life-saving.
Preliminary results of the individual working groups

Diagnosis and genetics
Francesco Muntoni and Brunhilde Wirth reported on the diagnosis and genetic working group. This included 11 physicians who were involved in various steps of the process.
After a review of the literature, 2 rounds of Delphi analysis were used to identify and rank in order of relevance the role of different diagnostic tests commonly used in SMA, to discuss the relevance of the number of SMN2 copies and their value in predicting severity of the phenotypes. The questions also investigated possible diagnostic scenarios to use if the SMN1 gene is not homozygously absent in an individual with features consistent with SMA. The final questions regarded genetic topics that were thought to be important to discuss with SMA patients and their families. There was consensus that genetic testing is the first line investigation when this condition is suspected in a typical case and that muscle biopsy or electromyography should not be performed in a typical presentation. There was also consensus that, at variance with previous recommendations, the current gold standard is SMN1 deletion/mutation and SMN2 copy number testing, with a minimal standard of SMN1 deletion testing. Other areas concerning the value of SMN2 copy number were more controversial and a further Delphi round was planned to complete the task.
Pulmonary
Anita Simonds and Hank Mayer reported on the pulmonary working group. This included 11 physicians for the medical aspects and one patient and two parents to share their opinion on possible other aspects that the patients/caregivers believed to be important. After a review of the literature, the first round was designed to use open questions to identify the recent biggest advancements in respiratory care and the barriers to providing effective pulmonary care in patients with SMA. Questions were also asked to identify the most important aspects of pulmonary morbidity, the most useful assessments of respiratory function and the most important supportive respiratory therapies in SMA.
The second round, including also patient representatives, aimed at ranking the best aspects of care, monitoring or pulmonary issues. As there seemed to be overlapping opinion, not consensus, a third additional round of questions was sent out to more deeply evaluate the strategies.
Preliminary results were shown for each of these aspects. There were consensus and reasonable data showing that both assisted airway clearance and non-invasive ventilation were helpful in SMA-1 and SMA-2. There was also consensus on when to start both interventions, and initiate NIV but there was less agreement on how to initiate mechanical insufflationexsufflation for secretion clearance. For type 1 there was consensus based on both literature and expert opinion for the pre-symptomatic initiation of both assisted airway clearance and non-invasive ventilation, i.e. "proactive care" as compared to "reactive care".
Following discussion, it was agreed that a 4th round of Delphi was needed to complete the task.
Acute management
Mary Schroth reported on the acute management working group. This included 13 physicians. After a review of the literature, the first round was designed to use open questions to identify the most important aspects of acute care. More specifically, the questions investigated the most important concerns when an individual with SMA develops an acute illness, starting from the advice given to families when someone with SMA becomes ill at home and issues regarding transportation to a medical facility. The questions also regarded the most important concerns when someone with SMA is hospitalized and/or requires surgery. The first round of responses provided a large number of possible interventions with some common key themes. This focused upon the need for anticipatory planning between families and care providers for acute illness management, and with the creation of documents such as a check-list or electronic medical record-accessible documents. A second round of Delphi was in progress to rank the open responses obtained in the first round.
Nutrition, growth and bone health
Enrico Bertini and Rebecca Hurst Davis reported on this working group. There were 15 participants. The first Delphi was completed and the second one was pending analysis at the time of the workshop. There are many questions regarding appropriate nutrition for individuals with SMA. This WG sought to expand the nutrition section from the previous consensus statement, which provided information on safe swallowing as well as GI dysmotility. Nutrition affects all individuals with SMA because everybody requires essential nutrients to survive. However, aspects of diet are affected by individual circumstances, specific needs, and degree of intervention desired by the individual and families. Since there are few nutrition studies specifically targeting SMA, experts relied on clinical experience as well as small studies and animal studies to make recommendations. It was acknowledged that there is much more research to be done in this area, but still sought consensus and understanding to define best nutrition practices for individuals with SMA. The literature review supported proactive nutrition support. Also, there are reports of increased glucagonemia in the mouse model and alpha cells in pancreas in type 1 patients and elevated insulin levels in type 2 patients, with risk of both hyper-and hypo-glycemia.
Ethics and palliative care
Simon Woods and Thomas Crawford presented this working group. Dr. Woods summarized the deliberations of the working group, an interdisciplinary group of 11 members, including clinicians, bioethics researchers, parents and patient representatives, and pediatric palliative care specialists. The literature review on this theme indicated that there is a very diverse literature which includes important contributions from clinical, social science and bioethics literature. The clinical literature provided little hard evidence and no consensus regarding standards of palliative care as applied to SMA. The working group was therefore unable to establish a consensus but identified 3 key areas for future analysis: (1) The concept of palliative care as applied to SMA, (2) Patient management and decision-making, (3) Managing expectations.
Although the concept of palliative care has been defined and re-interpreted many times there is a need to regard this as an ongoing reflexive process especially when applied to contexts, like SMA, that are not static. This should also be reviewed in consideration of the recent advances in SMA therapeutics that have created substantial reason for hope for changes in prognosis.
Physical therapy and rehabilitation
Jacqueline Montes, Elena Mazzone and Marion Main summarized the Physical Therapy and Rehabilitation WG. There were 12 participants: 10 physical therapists, 1 occupational therapist, and 1 physiatrist. Two patients with SMA participated: one adult with type 3, one adolescent with type 2 and one parent of a child with type 1. Three participants from the pharmaceutical industry contributed. A literature review included 5 search terms and 54 papers were reviewed with each characterized for quality. Two rounds of Delphi and four conference calls were conducted prior to the workshop. An impact score was generated and consensus was determined by evaluation of the variance of the ranking scores, with low variance representing a high level of agreement.
Topics important to address in non-sitters include pulmonary function, muscle weakness, postural control and contractures. Clinical evaluations should include administering the CHOP INTEND infant motor scale and assessment of head control and body posture.
For sitters, the main objectives identified for rehabilitation are to prevent contractures and scoliosis, maintain joint mobility, and maintain, restore or promote function and mobility. Clinical evaluations for sitters should include postural control and functional scales, such as the Hammersmith Functional Motor Scale Expanded.
Exercise programs were thought to be most important for walkers. Clinical evaluations for walkers should include administering timed function tests including the six-minute walk test.
The frequency with which rehabilitation services should be minimally provided was difficult to address with limited evidence in the literature, but it was thought to be important to define.
Orthopaedics
Michael Vitale and Brian Snyder presented the Orthopedic WG summary remotely, with contributions by Susana QuijanoRoy at the workshop. There were 13 members in this WG. Results were shared with participants from pharmaceutical companies but not with parents or patients.
Two rounds of Delphi were performed, and included approximately 30 questions within 6 topics. The main topics were: a. Identification of the optimal timing of spinal instrumentation for correction of scoliosis. b. Management of contractures: there are no accepted surgical guidelines or indications in the literature for the surgical treatment of joint contractures in SMA. c. Orthosis. There was divided consensus on the use of a thoracolumbosacral orthoses (TLSO) to specifically prevent progression of scoliosis in skeletally immature patients with SMA.
Other organ system involvement
Jan Kirschner presented a summary of their activities. There were 16 members in this WG, including participants from pharmaceutical companies and patients.
Two rounds of Delphi were performed. The main topics were related to a possible heart, liver, kidney or brain or metabolic involvement. There was consensus that other organ systems involvement is generally rare in SMA, but probably more common in severely affected patients.
Routine diagnostic testing was not recommended and should rather be based on clinical symptoms. Metabolic monitoring was suggested in non-ambulant patients during illness and/or fasting.
Medication
Many participants addressed the need to review the use of medications in common use for the management of patients with SMA. It was decided that a separate survey should be conducted following the workshop to address this topic.
Open discussion
Additional topics that need to be addressed: dental care, care of the pregnant woman with SMA and sexuality.
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